Autologous T-cell proliferation in the presence of MVA-TRICOM–infected CLL cells
Patient, stimulator cells . | Autologous stimulation index . |
|---|---|
| 2 | |
| Uninfected | 1.0 |
| MVA-WT | 0.5 |
| MVA-TRICOM | 34.8 |
| 8 | |
| Uninfected | 1.3 |
| MVA-WT | 1.6 |
| MVA-TRICOM | 30.6 |
| 16 | |
| Uninfected | 1.7 |
| MVA-WT | 1.3 |
| MVA-TRICOM | 27.2 |
| 13 | |
| Uninfected | 1.1 |
| MVA-WT | 1.0 |
| MVA-TRICOM | 13.4 |
| 14 | |
| Uninfected | 1.3 |
| MVA-WT | 0.7 |
| MVA-TRICOM | 5.3 |
| 12 | |
| Uninfected | 1.1 |
| MVA-WT | 1.3 |
| MVA-TRICOM | 4.2 |
| 19 | |
| Uninfected | 1.7 |
| MVA-WT | 1.3 |
| MVA-TRICOM | 2.3 |
| 10 | |
| Uninfected | 0.7 |
| MVA-WT | NA |
| MVA-TRICOM | 2.2 |
| 18 | |
| Uninfected | 1.0 |
| MVA-WT | 1.1 |
| MVA-TRICOM | 1.9 |
| 17 | |
| Uninfected | 1.1 |
| MVA-WT | 1.3 |
| MVA-TRICOM | 1.4 |
Patient, stimulator cells . | Autologous stimulation index . |
|---|---|
| 2 | |
| Uninfected | 1.0 |
| MVA-WT | 0.5 |
| MVA-TRICOM | 34.8 |
| 8 | |
| Uninfected | 1.3 |
| MVA-WT | 1.6 |
| MVA-TRICOM | 30.6 |
| 16 | |
| Uninfected | 1.7 |
| MVA-WT | 1.3 |
| MVA-TRICOM | 27.2 |
| 13 | |
| Uninfected | 1.1 |
| MVA-WT | 1.0 |
| MVA-TRICOM | 13.4 |
| 14 | |
| Uninfected | 1.3 |
| MVA-WT | 0.7 |
| MVA-TRICOM | 5.3 |
| 12 | |
| Uninfected | 1.1 |
| MVA-WT | 1.3 |
| MVA-TRICOM | 4.2 |
| 19 | |
| Uninfected | 1.7 |
| MVA-WT | 1.3 |
| MVA-TRICOM | 2.3 |
| 10 | |
| Uninfected | 0.7 |
| MVA-WT | NA |
| MVA-TRICOM | 2.2 |
| 18 | |
| Uninfected | 1.0 |
| MVA-WT | 1.1 |
| MVA-TRICOM | 1.9 |
| 17 | |
| Uninfected | 1.1 |
| MVA-WT | 1.3 |
| MVA-TRICOM | 1.4 |
CD3+ T cells from patients with CLL were stimulated with uninfected, MVA-WT-, or MVA-TRICOM–infected CLL cells, at a ratio of stimulator to effector cells equal to 1:2.5. Proliferation was measured as 3H-thymidine incorporation on day 5 of culture. Stimulation index was calculated as cpm (T cells + CLL cells)/cpm (T cells alone).
NA indicates not available.